Insider Trading activities of Spero Therapeutics, Inc. insiders.

Monthly summaries of insider trading activities (stock purchases, sales, and option exercises) reported by insiders of Spero Therapeutics, Inc. since 2005 are illustrated in Table 1 and Table 2. Table 1 shows the monthly insider trading data of Spero Therapeutics, Inc. since year 2005. Table 2 shows the detailed insider transactions of Spero Therapeutics, Inc. since 2005. The reporting company's ticker symbol is SPRO. The reporting company's CIK number is 1701108.
The total value of stock buying since 2005 is $21,090,972.
The total value of stock sales since 2005 is $0.
The total value of stock option exercises since 2005 is $0.


Table 1. Monthly summaries of insider stock purchases, sales, and option exercises for Spero Therapeutics, Inc. (SPRO).
Trading Period Insider Buying Insider Sales Option Exercises
year-month Shares Value Shares Value Shares Value
2017-11 1,506,498 $21,090,972 0 $0 0 $0

Table 2. Detailed insider stock purchases, sales, and option exercises of Spero Therapeutics, Inc. insiders (SPRO)
  Trade Date   Insider Name Trade Type     Shares       Price ($)   Value ($)
2017-11-06 Larkin Cristina (Chief Operating Officer) Buy 1,500 14.00 21,000
2017-11-06 Goyal Vikas (Director) Buy 428,571 14.00 5,999,994
2017-11-06 Sendek Joel (Chief Financial Officer) Buy 5,000 14.00 70,000
2017-11-06 Breum Casper (Director) Buy 214,285 14.00 2,999,990
2017-11-06 Glaxosmithkline Plc Buy 428,571 14.00 5,999,994
2017-11-06 Formela Jean Francois (Director) Buy 428,571 14.00 5,999,994

Insider trading activities including stock purchases, stock sales, and option exercises of SPRO listed in the above tables cannot be completely guaranteed as to their accuracy. For more insider trading information of Spero Therapeutics, Inc. (symbol SPRO, CIK number 1701108) see the Securities and Exchange Commission (SEC) website.